Skip to main content
SpringerLink
Log in

Neuroendokrine Neoplasien des Magens

  • Living reference work entry
  • Latest version View entry history
  • First Online:
DGIM Innere Medizin

Part of the book series: Springer Reference Medizin ((SRM))

  • 10 Accesses

Zusammenfassung

Mit ein bis zwei Erkrankungen pro 1.000.000 Personen pro Jahr handelt es sich bei den Neoplasien des Magens um eine sehr seltene Tumorentität. Bezogen auf alle gastrointestinalen neuroendokrinen Neoplasien (gen) sind circa 9 % primär gastrale Neoplasien. Hauptlokalisation sind Magenfundus und -korpus. Die neuroendokrinen Neoplasien des Magens sind in drei bzw. vier Subtypen unterteilt. Das therapeutische Vorgehen hängt neben dem Subtyp der gastralen neuroendokrinen Neoplasie von Funktionalität, Differenzierungsgrad, Stadium, ECOG-Performance-Status und nicht zuletzt der Komorbidität des Patienten ab. Prognostisch bestehen erhebliche Unterschiede zwischen den Genen-Subtypen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Bois A du, Lück HJ, Meier W et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320–1329

    Google Scholar 

  • Bordi C (1999) Gastric carcinoids. Ital J Gastroenterol Hepatol 31(Suppl 2):94–97

    Google Scholar 

  • Chan D, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj NP et al (2019) Temozolomide in grade III neuroendocrine neoplasms (G3 NENs): a multicenter retrospective review. J Clin Oncol 37:321

    Article  Google Scholar 

  • Delle Fave G, O‘Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, Ferone D, Ito T, Weber W, Zheng-Pei Z, De Herder WW, Pascher A, Ruszniewski P, Vienna Consensus Conference participants (2016) ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms. Neuroendocrinology. 103(2):119–124. https://doi.org/10.1159/000443168. Epub 2016 Jan 19. PMID: 26784901

    Article  CAS  PubMed  Google Scholar 

  • Klöppel G (2003) Vom-Karzinoid-zum-neuroendokrinen-Tumor-Klassifizierung-im-Magen-Darm-Trakt-und-Pankreas. Dtsch Arztebl 100(28–29):A-1932/B-1605/C-1513

    Google Scholar 

  • Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934–959

    Article  PubMed  Google Scholar 

  • Moertel CG, Kvols LK, O’Connell MJ et al (1991) Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227–232

    Article  CAS  PubMed  Google Scholar 

  • Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J, Japan Clinical Oncology Group (JCOG) (2022) Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial. JAMA Oncol. 8(10):1447–1455. https://doi.org/10.1001/jamaoncol.2022.3395. PMID: 35980649; PMCID: PMC9389440

    Article  PubMed  PubMed Central  Google Scholar 

  • Pavel M, Baudin E, Couvelard A, Krenning E et al (2012) ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157–176

    Article  CAS  PubMed  Google Scholar 

  • Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A, ESMO Guidelines Committee (2020) Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 31(7):844–860. https://doi.org/10.1016/j.annonc.2020.03.304. Epub 2020 Apr 6. PMID: 32272208

    Article  CAS  PubMed  Google Scholar 

  • RAMSETE (o.J.) RAD001 in advanced and metastatic silent neuro-endocrine tumors in Europe (RAMSETE/CDE16)

    Google Scholar 

  • Rappel S, Altendorf-Hofmann A, Stolte M (1995) Prognosis of gastric carcinoid tumours. Digestion 56(6):455–462

    Article  CAS  PubMed  Google Scholar 

  • Rindi G, Azzoni C, La Rosa S et al (1999) ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116:532–542

    Article  CAS  PubMed  Google Scholar 

  • Rinke A, Muller HH, Schade-Brittinger C et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663

    Article  CAS  PubMed  Google Scholar 

  • Strosberg J, Coppola D, Klimstra DS et al (2010) The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 39:799–800

    Article  PubMed  PubMed Central  Google Scholar 

  • Welin S, Sorbye H, Sebjornsen S et al (2011) Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 11:4617–4622

    Article  Google Scholar 

  • Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 387:968–977

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Hämatologie und Onkologie Universitätsklinikum Schleswig-Holstein, Lübeck, Deutschland

    Kim Luley

Authors
  1. Kim Luley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kim Luley .

Editor information

Editors and Affiliations

  1. Universität Salzburg, Salzburg, Österreich

    Hendrik Lehnert

  2. Innere Medizin IV, Helios Dr. Horst Schmidt Kliniken Wiesba, Wiesbaden, Deutschland

    Elisabeth Märker-Hermann

  3. Medizinische Klinik I, Universitätsklinikum Aachen, RWTH Aache, Aachen, Nordrhein-Westfalen, Deutschland

    Nikolaus Marx

  4. Institut für Endokrinologie & Diabetes, Universität zu Lübeck, Lübeck, Deutschland

    Sebastian M. Meyhöfer

Section Editor information

  1. Klinik für Hämatologie und Onkologie, Universitätsklinikum Schleswig-Holstein, Lübeck, Deutschland

    Nikolas von Bubnoff

  2. Klinik für Hämatologie und Onkologie, Universitätsklinikum Schleswig-Holstein, Lübeck, Deutschland

    Kim Luley

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Luley, K. (2023). Neuroendokrine Neoplasien des Magens. In: Lehnert, H., Märker-Hermann, E., Marx, N., Meyhöfer, S.M. (eds) DGIM Innere Medizin. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-54676-1_509-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54676-1_509-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-54676-1

  • Online ISBN: 978-3-642-54676-1

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Neuroendokrine Neoplasien des Magens
    Published:
    27 August 2023

    DOI: https://doi.org/10.1007/978-3-642-54676-1_509-2

  2. Original

    Neuroendokrine Neoplasien des Magens
    Published:
    13 October 2015

    DOI: https://doi.org/10.1007/978-3-642-54676-1_509-1

Search

Navigation